Foam dressing biocompatibility testing is the mandatory biological safety evaluation performed on polyurethane and silicone foam wound dressings in accordance with the ISO 10993 series of standards. Because foam dressings are surface medical devices that remain in contact with breached or compromised skin for prolonged periods, they must demonstrate acceptable results in cytotoxicity, sensitization, irritation, and systemic toxicity tests before regulatory submission. This article explains the applicable standards, sample preparation requirements, core test items, testing methods, and frequently asked questions related to foam dressing biocompatibility assessment.
Technical Overview
Foam dressings are soft, highly absorptive wound care products typically constructed from a polyurethane foam matrix, a silicone or hydrophilic wound contact layer, and a polyurethane film backing. They are indicated for moderate to heavily exuding wounds such as pressure ulcers, venous leg ulcers, diabetic foot ulcers, and surgical wounds. Some variants incorporate antimicrobial agents such as silver, which can significantly influence the biological safety evaluation strategy.
Under the framework of ISO 10993-1 (identically adopted in China as GB/T 16886.1 and in Europe as EN ISO 10993-1), foam dressings are classified as surface medical devices contacting breached or compromised surfaces, with a contact duration that is usually categorized as prolonged (24 hours to 30 days), since dressings are typically worn for several days before replacement. Based on the endpoint selection matrix in ISO 10993-1:2018, this contact category requires evaluation of cytotoxicity, sensitization, irritation, acute systemic toxicity, subacute systemic toxicity, material-mediated pyrogenicity, and consideration of genotoxicity, supported where appropriate by chemical characterization and toxicological risk assessment.
Biocompatibility testing should follow a risk-based approach integrated with the manufacturer's quality management system. Test articles must represent the final product in its sterilized, ready-to-use condition, including all materials and processing aids that could migrate into the wound. All biological evaluations should be performed by accredited third-party laboratories or qualified in-house facilities operating under GLP or ISO/IEC 17025 quality systems.
Testing Samples
Finished Device Samples
The preferred test article is the intact, sterilized foam dressing as supplied to the end user, because sterilization, adhesive layers, carrier films, and packaging can all contribute to the extractable chemical profile. Samples should be selected from representative production lots manufactured under final process conditions. For a complete test battery covering cytotoxicity, sensitization, irritation, and systemic toxicity, laboratories typically require dozens of dressings depending on product dimensions and the test plan.
Component and Material Samples
Individual components, such as the polyurethane foam, silicone gel adhesive, perforated contact film, and absorbent core, may be tested separately when new suppliers are introduced, when a material formulation changes, or when a component supplier provides material master files. Component-level testing supports comparative evaluations and can justify abbreviated test programs when only a non-contact layer has changed.
Extract Preparation
Most biocompatibility tests are performed on extracts rather than the device itself. In accordance with ISO 10993-12, extraction is conducted in polar media (physiological saline or cell culture medium with serum) and non-polar media (such as sesame oil) at a standard surface-area-to-volume ratio, commonly 6 cm²/mL for materials up to 0.5 mm thick and 3 cm²/mL for thicker materials. Standard extraction conditions include 37°C for 72 hours, 50°C for 72 hours, or 70°C for 24 hours, selected to simulate clinical use without thermally degrading the material or generating unrealistic extraction artifacts.
Testing Items
The core biocompatibility test battery for a typical foam dressing includes the following items, each governed by a specific part of the ISO 10993 series:
- In vitro cytotoxicity in accordance with ISO 10993-5
- Skin sensitization in accordance with ISO 10993-10
- Skin irritation and intracutaneous reactivity in accordance with ISO 10993-23 and ISO 10993-10
- Acute systemic toxicity in accordance with ISO 10993-11
- Subacute or subchronic systemic toxicity in accordance with ISO 10993-11
- Material-mediated pyrogenicity in accordance with ISO 10993-11
- Genotoxicity screening (bacterial reverse mutation assay and mammalian chromosome aberration assay) in accordance with ISO 10993-3, when warranted by the chemical characterization
- Chemical characterization of extractables and leachables in accordance with ISO 10993-18
- Toxicological risk assessment in accordance with ISO 10993-17
- Ethylene oxide residue testing in accordance with ISO 10993-7 when the dressing is sterilized by ethylene oxide
- Hemocompatibility in accordance with ISO 10993-4 only for designs claiming blood contact or use on actively bleeding wounds
Testing Methods
Cytotoxicity Testing
The extract (elution) method is the most widely applied approach. Test extracts are applied to monolayers of L929 mouse fibroblast cells or another appropriate mammalian cell line for 24 hours at 37°C. Results are evaluated qualitatively by microscopic grading of cell morphology on a 0 to 4 scale and quantitatively using colorimetric viability assays such as MTT reduction. A cell viability of at least 70 percent relative to the blank control extract constitutes a pass. Direct contact and agar diffusion (indirect contact) methods are available for specific product geometries where extraction may not represent clinical exposure.
Sensitization Testing
Intracutaneous reactivity testing in rabbits remains the reference method for foam dressings. Polar and non-polar extracts are injected intracutaneously at paired sites, and erythema and edema are scored at 24, 48, and 72 hours; the combined primary irritation index must not exceed the acceptance criterion defined in the standard. ISO 10993-23 also recognizes reconstructed human epidermis (RhE) in vitro skin irritation models, which may replace animal testing for many finished-device configurations when scientifically justified.
Systemic Toxicity and Pyrogenicity
Acute systemic toxicity is assessed by single intravenous or intraperitoneal injection of polar and non-polar extracts into mice, followed by observation for mortality and clinical signs of toxicity, typically over at least 72 hours. Subacute toxicity involves repeated exposure over 14 to 28 days where the risk assessment indicates a need. Material-mediated pyrogenicity is evaluated using the rabbit pyrogen test or justified through the toxicological assessment of characterized leachables.
Chemical Characterization and Toxicological Risk Assessment
Extractables and leachables studies employ gas chromatography-mass spectrometry (GC-MS), liquid chromatography-tandem mass spectrometry (LC-MS/MS), inductively coupled plasma mass spectrometry (ICP-MS), and infrared spectroscopy to identify and quantify migrating substances such as residual monomers, plasticizers, antioxidants, curing agents, and degradation products. Identified compounds are then evaluated against health-based exposure limits, safety margin calculations, and toxicological concern thresholds in line with ISO 10993-17. This chemistry-first approach frequently reduces or eliminates the need for additional animal testing.
Applications
Biocompatibility test reports for foam dressings support multiple regulatory and quality objectives, including:
- NMPA medical device registration in China, evaluated against the GB/T 16886 series
- FDA 510(k) and PMA submissions in the United States, evaluated against ISO 10993-1 and corresponding FDA guidance
- EU MDR CE marking technical documentation, evaluated against EN ISO 10993 harmonized standards
- Assessment of design changes, material substitutions, and changes to adhesive or foam suppliers
- Evaluation of sterilization process changes, particularly ethylene oxide cycle modifications
- Biological safety files for antimicrobial foam dressings containing silver or other active agents
- Due-diligence support for OEM manufacturing and private-label product transfers
A complete biological evaluation report typically includes test reports from accredited third-party laboratories, a biological safety assessment, rationales for any omitted endpoints, and a documented gap analysis linking the test plan to the ISO 10993-1 endpoint matrix.
FAQ
Which biocompatibility tests are mandatory for a typical foam dressing?
For a standard foam dressing with prolonged contact on compromised skin, the baseline battery consists of cytotoxicity (ISO 10993-5), sensitization (ISO 10993-10), and irritation or intracutaneous reactivity (ISO 10993-23), supplemented by acute systemic toxicity and pyrogenicity as determined by the risk assessment. Genotoxicity, subacute toxicity, and chemical characterization are added when the wound contact duration, new materials, or chemical screening results indicate a need.
How long does a full biocompatibility test battery take?
Cytotoxicity testing typically requires two to four weeks, irritation and intracutaneous reactivity approximately four to six weeks, and sensitization protocols eight to twelve weeks including the acclimatization and observation phases. Chemical characterization and the subsequent toxicological risk assessment may require an additional six to twelve weeks depending on the complexity of the extractables profile.
Should testing be performed on the sterilized final product?
Yes. Biological evaluation must reflect the device as delivered to the clinic, including its final sterilization state. Ethylene oxide sterilization, gamma irradiation, and electron beam processing can each alter the extractable profile, so testing on pre-sterilization samples is generally unacceptable unless a formal justification is provided.
Can existing data or literature evaluations replace new animal testing?
Yes, when justified. ISO 10993-1 encourages a weight-of-evidence approach in which equivalent material data, supplier certifications, validated chemical characterization, and peer-reviewed toxicological literature can be used to waive specific in vivo endpoints. Such waivers must be documented by a qualified toxicologist in the biological safety assessment file.
How many samples are required for testing?
Sample requirements depend on the dressing surface area and the number of extraction media and conditions. As a practical guide, laboratories usually request 30 to 100 finished dressings to cover cytotoxicity, sensitization, irritation, and acute systemic toxicity, with additional units reserved for chemical characterization and any repeat testing.
Do silver-containing antimicrobial foam dressings need additional testing?
Often yes. Silver ions and silver-releasing compounds can produce cytotoxic or irritant responses in standard assays, so the test strategy must distinguish between antimicrobial activity and genuine safety concerns. Extended chemical characterization for silver release kinetics, wound fluid simulation studies, and a compound-specific toxicological risk assessment are commonly required for these products.